• Cefepime in CNS Infection Research

  2026-08-18

  Cefepime (BMY-28142) offers translational researchers a mechanistically grounded platform for connecting β-lactam activity, blood–brain barrier exposure, resistance dynamics, and neurotoxicity readouts in central nervous system infection models.

• STING agonist-1: B-Cell Assay Workflows

  2026-08-18

  Use STING agonist-1 as a controlled perturbation for dissecting innate immune signaling, IRF4-associated B-cell activation, and tumor-immunity phenotypes. This workflow emphasizes dose finding, orthogonal readouts, pathway controls, and practical handling of a DMSO-soluble research reagent.

• Diethylmaleate for GSH Depletion Workflows

  2026-08-17

  Diethylmaleate provides a practical way to perturb glutathione-dependent defenses and connect redox changes with GST activity, ROS, apoptosis, and chemical resistance. This workflow-oriented guide translates insecticide-resistance evidence into controlled assay designs while separating validated findings from optimization recommendations.

• GDC-0994 ERK1/2 Inhibitor Workflows

  2026-08-17

  GDC-0994 provides a selective way to connect ERK1/2 signaling with measurable outcomes in BRAF- or RAS-driven cancer models and estrogen-associated cholestasis studies. This guide translates the reference findings into practical dosing, pathway-validation, and troubleshooting workflows.

• A-769662: Practical AMPK Activation Workflows

  2026-08-16

  A-769662 provides a reversible way to interrogate AMPK-driven energy metabolism without relying solely on nutrient starvation. This workflow-centered guide connects fatty acid synthesis inhibition, autophagy interpretation, and proteasome-related cell-cycle effects while emphasizing controls that separate AMPK-dependent from off-target biology.

• Nonselective β-Blockers and Hematopoietic Recovery

  2026-08-15

  The reference study shows that nonselective β-adrenergic receptor inhibitors can delay hematopoietic regeneration after allogeneic transplantation, whereas β1-selective inhibition with Metoprolol Tartrate was not associated with the same impairment in the tested models. Its integrated mouse and clinical analyses identify transplant type, posttransplant chemotherapy, and graft-cell dose as important modifiers of this association.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-08-14

  Anlotinib hydrochloride gives researchers a practical way to connect VEGFR2, PDGFRβ, and FGFR1 signaling with measurable endothelial migration, tube formation, and ERK responses. This workflow-focused guide covers assay setup, comparative benchmarking, translational interpretation, and troubleshooting for cancer research.

• A-769662: AMPK Activator Workflows

  2026-08-14

  A-769662 provides reversible, allosteric AMPK activation for dissecting energy metabolism, fatty acid synthesis inhibition, and nutrient-stress signaling. Its activity can also expose AMPK-independent proteasome effects, making parallel pathway and viability controls essential in metabolic and autophagy experiments.

• CX-4945 (Silmitasertib) in CK2 Lung Cancer Models

  2026-08-13

  CX-4945 (Silmitasertib) provides a mechanistic framework for studying CK2-driven stability, stemness, chemoresistance, and invasion in lung cancer. This article translates recent ECE-1c findings into practical assay and interpretation strategies.

• Cisapride for iPSC-CM Cardiac Safety Screens

  2026-08-13

  Cisapride (R 51619) combines 5-HT4 receptor activation with potent hERG channel inhibition, making it a useful mechanistic benchmark for cardiac electrophysiology research. This guide translates that dual pharmacology into iPSC-cardiomyocyte, high-content imaging, and orthogonal electrophysiology workflows with practical troubleshooting.

• Sulfaphenazole Restores Diabetic Vascular Function

  2026-08-12

  The reference study showed that pharmacological CYP2C inhibition with Sulfaphenazole restored acetylcholine-dependent vasodilation in db/db diabetic mice without lowering plasma glucose. Its key contribution was to connect CYP-derived oxidative stress with reduced nitric oxide bioavailability and impaired endothelial function, offering a mechanistic framework for vascular endothelial function research.

• Tamoxifen as a Mechanistic Probe in MCF-7 Assays

  2026-08-12

  Tamoxifen, a selective estrogen receptor modulator, can serve as more than a treatment control. This article explains how to use its pharmacology to interpret caveolin-1, migration, cytotoxicity, and CreER-mediated gene knockout experiments with greater mechanistic precision.

• Cell Counting Kit-8 in Mutant p53 Cancer Models

  2026-08-11

  Use CCK8 to quantify genotype-dependent proliferation, drug sensitivity, and viability in mutant p53 cancer models. A controlled WST-8 workflow can complement replication-stress and cGAS–STING studies while clarifying where metabolic readouts require orthogonal validation.

• Azithromycin and Roxithromycin as Senolytic Drugs

  2026-08-11

  The 2018 Aging study established a streamlined screening strategy that identified azithromycin and roxithromycin as senolytic agents against BrdU-induced senescent human fibroblasts. Its comparison with erythromycin, combined with viability, impedance, and metabolic analyses, suggests that macrolide structure and senescent-cell metabolism may influence drug selectivity.

• AZD3463: A Translational Strategy for ALK Biology

  2026-08-10

  AZD3463 offers translational researchers a dual ALK/IGF1R framework for studying neuroblastoma signaling, resistance biology, apoptosis, autophagy, and chemotherapy combinations. This article connects its reported pharmacology with disciplined experimental design and highlights how kinase-scaffold evidence should—and should not—be transferred across biological domains.

16284 records 1/1086 page Next 12345 下5页 Last page